TY - JOUR
T1 - Treatment Options for Osteoporosis
AU - Khosla, Sundeep
AU - Riggs, B. Lawrence
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1995
Y1 - 1995
N2 - The number of women affected by postmenopausal osteoporosis is likely to continue to increase substantially as the population ages. Furthermore, the therapeutic options for such patients are likely to increase. In this brief review, we outline the use of the currently available medications for the management of osteoporosis—namely, estrogen, calcitonin, calcium, and vitamin D. In addition, we discuss the next generation of drugs that are likely to become available in the future—the bisphosphonates and estrogen analogues. As these options become available, the prevention and treatment of osteoporosis will become similar to the management of other common disorders such as hypertension or hyperlipidemia, in which the most appropriate medication may differ for individual patients. Thus, the treatment of osteoporosis is likely to evolve from a decision of whether to initiate estrogen replacement therapy to a more complex decision of the best agent to use for an individual patient.
AB - The number of women affected by postmenopausal osteoporosis is likely to continue to increase substantially as the population ages. Furthermore, the therapeutic options for such patients are likely to increase. In this brief review, we outline the use of the currently available medications for the management of osteoporosis—namely, estrogen, calcitonin, calcium, and vitamin D. In addition, we discuss the next generation of drugs that are likely to become available in the future—the bisphosphonates and estrogen analogues. As these options become available, the prevention and treatment of osteoporosis will become similar to the management of other common disorders such as hypertension or hyperlipidemia, in which the most appropriate medication may differ for individual patients. Thus, the treatment of osteoporosis is likely to evolve from a decision of whether to initiate estrogen replacement therapy to a more complex decision of the best agent to use for an individual patient.
UR - http://www.scopus.com/inward/record.url?scp=0029391604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029391604&partnerID=8YFLogxK
U2 - 10.4065/70.10.978
DO - 10.4065/70.10.978
M3 - Article
C2 - 7564551
AN - SCOPUS:0029391604
SN - 0025-6196
VL - 70
SP - 978
EP - 982
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 10
ER -